Bio-Gene Technology Limited (BGT.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.017 (+0.00%) as of
Key statistics
- Market cap
- 7.45M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0125 – 0.0490
- Beta
- 0.79
- Revenue (TTM)
- 1.08M
- Profit margin
- -216.04%
- Volume
- 174.00
About Bio-Gene Technology Limited
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning biomass prior to distillation; Cesar for assessing the insecticidal activity of its molecules against a range of insect species; Advanced Molecular Technologies; CSIRO for a chemistry development process; the Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University for chemical analysis of natural products; University of Florida; and University of Technology. It serves animal health, crop protection, grain storage, public health, and consumer applications. The company was incorporated in 1995 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.